The N-terminal half of the receptor domain of botulinum neurotoxin A binds to microdomains of the plasma membrane

Botulinum neurotoxin type A (BoNT/A) is largely employed in human therapy because of its specific inhibition of peripheral cholinergic nerve terminals. BoNT/A binds to them rapidly and with high specificity via its receptor binding domain termed HC. Recent evidence indicate that BoNT/A interacts spe...

Ausführliche Beschreibung